SPECIAL FEATURE - Patients & Physicians Desire Transdermal, Topical & Subcutaneous Delivery July 9, 2014

Contributor Cindy H. Dubin recently interviewed several topical, transdermal, and subcutaneous product manufacturers to find out how they are working with patients and physicians to develop delivery systems that meet their needs for comfort, compliance, and more effective delivery.

FORMULATING PEPTIDES - Novel Formulations for Non-Invasive Delivery & Stabilization of Peptides October 15, 2013

Edward T. Maggio, PhD, examines how alkylsaccharides offer exciting prospects for novel formulations, providing non-invasive delivery, stabilization, and immunogenicity reduction for biotherapeutic products, resulting in broader patient acceptance and compliance and an increase in their acceptance as viable commercial pharmaceuticals.

SPECIAL FEATURE - Transdermal, Topical & Subcutaneous Drug Delivery: Extending Pipelines & Improving Self-Administration July 20, 2013

Contributor Cindy H. Dubin explores how the movement of home care and self- administration is pushing the development of this growing sector in drug delivery.

ADVANCED DELIVERY DEVICES - IntelliCap: An Intelligent, Electronic Capsule for Oral Drug Delivery & Development March 31, 2013

Jeff Shimizu and Christoph Wanke, PhD, indicate electronic smart pills represent an emerging area with great potential for growth. Already established in the diagnostic area, the next move is into monitoring and drug delivery.

INNOVATION AWARDS - Drug Delivery Award Winners Move Innovation Needle; Formulation Takes Center Stage March 31, 2013

Marc Dresner presents the three companies that were honored by their industry peers with prestigious awards for breakthrough drug delivery innovation at the Institute for International Research’s 17th annual Drug Delivery Partnerships conference.

Encap Drug Delivery Introduces Colon-Screen August 18, 2011

SPECIAL FEATURE - Excipients: Advanced Biologics Require Innovative Excipient Science March 29, 2024

Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.

VACCINE DEVELOPMENT - A Healthier Global Population Through a Universal Influenza & Multi-Virus Vaccine February 28, 2024

Jeff Fischer, MBA, says we need to have an eye toward universal influenza or multi-virus vaccines that have the ability to provide broad coverage as viral strains continue to evolve.

FORMULATION FORUM - LIPIDSOL®: Liposomes - Chemistry, Properties & Applications of Lipid Nanoparticles May 1, 2023

Jim Huang, PhD, and Shaukat Ali, PhD, describe their LNP platform as well as the latest trends in LNPs as more and more novel therapeutic modalities discovered can’t be handled by traditional microemulsions or nanoemulsions.

EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems May 1, 2023

Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.

Bhami Research Laboratory & Catalent Enter Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously March 16, 2023

SPECIAL FEATURE - Solubility & Bioavailability: Difficult Beasts to Tame March 1, 2023

Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.

EXECUTIVE INTERVIEW - Alcami: Unlocking the Potential of Transformative Medicine for 40 Years November 30, 2022

Mike Babics, Vice President, Parenteral Services at Alcami, discusses the company’s recent expansions in formulation and analytical development, manufacturing, release testing, and biostorage of clinical and commercial drug products for both solid dosage and parenteral products.

EXTRACELLULAR VESICLES - Engineering Extracellular Vesicles to Create Next-Generation Therapeutics October 3, 2022

David Lowe, PhD, Justin Hean, PhD, Dave Carter, PhD, and Antonin de Fougerolles, PhD, say EVs exhibit key properties that make them extremely attractive as therapeutics, particularly their safety profile and potential for low immunogenicity. In order to effectively unlock this potential, some key challenges remain, such as the development of EV product manufacture and characterization methodologies and rapid pharmacokinetics.

Enteris BioPharma to Exhibit at CPhI North America 2022 May 9, 2022

Enteris BioPharma Highlighted as Game Changer in Special Feature on Innovative Technologies for Improving Drug Solubility & Bioavailability April 7, 2022

SPECIAL FEATURE - Excipients: Exciting Expansion & Innovation April 4, 2022

Contributor Cindy H. Dubin speaks with several companies and presents a unique look at how excipients are being used to support current and future innovative active pharmaceutical ingredients.

Enteris BioPharma to Participate in DCAT® Week 2022 March 1, 2022

SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022

Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.

Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services January 20, 2022

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), recently announced the launch….

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

Where Do We Stand on Poorly Soluble Drugs and Peptides in Oral Delivery?

The Rule of 5 suggests that, for oral bioavailability, a better chance for oral absorption is obtained when the molecules are within the parameters of the Rule of 5’. However, the pharmaceutical industry is achieving oral efficacy with drugs that exceed….

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

This paper covers the benefits of the LBF and capsules combination in dosage form developments, an efficient technology platform to bring efficient and differentiated products to the market.

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges